DK0912601T4 - Suppression af immunrespons ved inhibering af cathepsin S - Google Patents
Suppression af immunrespons ved inhibering af cathepsin SInfo
- Publication number
- DK0912601T4 DK0912601T4 DK97921360T DK97921360T DK0912601T4 DK 0912601 T4 DK0912601 T4 DK 0912601T4 DK 97921360 T DK97921360 T DK 97921360T DK 97921360 T DK97921360 T DK 97921360T DK 0912601 T4 DK0912601 T4 DK 0912601T4
- Authority
- DK
- Denmark
- Prior art keywords
- class
- cathepsin
- mhc
- methods
- immune response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1810096P | 1996-04-22 | 1996-04-22 | |
PCT/US1997/006865 WO1997040066A1 (fr) | 1996-04-22 | 1997-04-22 | Suppression de reponse immunitaire par inhibition de cathepsine s |
Publications (2)
Publication Number | Publication Date |
---|---|
DK0912601T3 DK0912601T3 (da) | 2004-03-29 |
DK0912601T4 true DK0912601T4 (da) | 2009-03-09 |
Family
ID=21786243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97921360T DK0912601T4 (da) | 1996-04-22 | 1997-04-22 | Suppression af immunrespons ved inhibering af cathepsin S |
Country Status (12)
Country | Link |
---|---|
US (4) | US6608030B1 (fr) |
EP (1) | EP0912601B2 (fr) |
JP (1) | JP2000509376A (fr) |
AT (1) | ATE255126T1 (fr) |
AU (1) | AU723447B2 (fr) |
CA (1) | CA2251714A1 (fr) |
DE (1) | DE69726426T3 (fr) |
DK (1) | DK0912601T4 (fr) |
ES (1) | ES2208898T5 (fr) |
NZ (1) | NZ332390A (fr) |
PT (1) | PT912601E (fr) |
WO (1) | WO1997040066A1 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037667A1 (fr) * | 1998-01-23 | 1999-07-29 | Microcide Pharmaceuticals, Inc. | Inhibiteurs de pompe d'ecoulement |
US6204279B1 (en) * | 1998-06-03 | 2001-03-20 | Microcide Pharmaceuticals, Inc. | Peptidomimetic efflux pump inhibitors |
JP2002517208A (ja) * | 1998-06-04 | 2002-06-18 | リプロゲン,インコーポレイティド | 子宮内膜症の診断および治療におけるカテプシンの使用 |
GB9911417D0 (en) * | 1999-05-18 | 1999-07-14 | Peptide Therapeutics Ltd | Furanone derivatives as inhibitors of cathepsin s |
AU2001281255B2 (en) | 2000-08-14 | 2006-07-20 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
US6635633B2 (en) | 2000-08-14 | 2003-10-21 | Ortho-Pharmaceutical, Inc. | Substituted pyrazoles |
RU2317988C2 (ru) | 2000-08-14 | 2008-02-27 | Орто-Макнейл Фармасьютикал, Инк. | Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s |
US7332494B2 (en) | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
EP1315966B1 (fr) | 2000-09-06 | 2007-10-03 | Ortho-McNeil Pharmaceutical, Inc. | Procede relatif au controle de l'effet d'inhibiteurs de cathepsine s |
WO2002020002A2 (fr) * | 2000-09-06 | 2002-03-14 | Ortho Mcneil Pharmaceutical, Inc. | Methode de traitement des allergies |
US20030144234A1 (en) * | 2001-08-30 | 2003-07-31 | Buxton Francis Paul | Methods for the treatment of chronic pain and compositions therefor |
US6780985B2 (en) * | 2001-11-08 | 2004-08-24 | Ortho-Mcneil Pharmaceutical, Inc. | Polynucleotide and polypeptide sequences of Canine Cathepsin S |
JP2003287139A (ja) * | 2002-03-29 | 2003-10-10 | Uchiyama Mfg Corp | ガスケット |
US7101880B2 (en) * | 2002-06-24 | 2006-09-05 | Schering Aktiengesellschaft | Peptidic compounds as cysteine protease inhibitors |
US7319016B1 (en) | 2002-08-23 | 2008-01-15 | Takeda San Diego, Inc. | Crystallization of cathepsin S |
BRPI0409868A (pt) * | 2003-04-28 | 2006-05-16 | Novartis Ag | composição farmacêutica que compreende um inibidor da catepsina s e um opióide |
WO2005028424A1 (fr) * | 2003-09-23 | 2005-03-31 | Merck Frosst Canada Ltd. | Dosage de cellule entiere associe a la cathepsine s |
JP2007513972A (ja) * | 2003-12-11 | 2007-05-31 | アクシス・ファーマシューティカルズ・インコーポレイテッド | 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンsインヒビターの使用 |
JP2007516295A (ja) * | 2003-12-23 | 2007-06-21 | アクシス・ファーマシューティカルズ・インコーポレイテッド | システインプロテアーゼインヒビターとしてのアミジノ化合物 |
BRPI0506494A (pt) * | 2004-01-30 | 2007-02-13 | Schering Ag | compostos de silinano como inibidores de cisteìna protease |
CA2648947A1 (fr) * | 2006-04-10 | 2007-11-15 | Fusion Antibodies Limited | Therapie ciblant la cathepsine s |
US20100266577A1 (en) * | 2007-07-25 | 2010-10-21 | Felipe Samaniego | Method of Cancer Treatment with Antagonists of FAS Inhibitors |
US20100331545A1 (en) * | 2007-10-24 | 2010-12-30 | Nippon Chemiphar Co., Ltd. | Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
EP2198879A1 (fr) | 2008-12-11 | 2010-06-23 | Institut Curie | Agent modulateur de CD74 pour la régulation de la migration de cellules dendritiques et dispositif pour l'étude de la capacité de motilité d'une cellule |
WO2010070615A1 (fr) | 2008-12-19 | 2010-06-24 | Medivir Uk Ltd | Inhibiteurs de cystéine protéase |
JP2013534917A (ja) * | 2010-06-16 | 2013-09-09 | メディヴィル・ユーケイ・リミテッド | 自己免疫障害、アレルギー、及び慢性疼痛状態、等の治療に有用な新規カテプシンsプロテアーゼ阻害剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020357A1 (fr) | 1991-05-23 | 1992-11-26 | Merrell Dow Pharmaceuticals Inc. | Inhibiteurs de la cathepsine g et de l'elastase empechant la degradation du tissu conjonctif |
WO1994004557A1 (fr) | 1992-08-11 | 1994-03-03 | President And Fellows Of Harvard College | Peptides immunomodulateurs |
DK0603769T3 (da) | 1992-12-25 | 1999-06-14 | Mitsubishi Chem Corp | Alfa-aminoketonderivater |
US5559028A (en) | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
IL112759A0 (en) * | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
US5501969A (en) | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
PL322409A1 (en) | 1995-03-24 | 1998-01-19 | Arris Pharm Corp | Reversible protease inhibitors |
-
1997
- 1997-04-22 NZ NZ332390A patent/NZ332390A/xx not_active IP Right Cessation
- 1997-04-22 CA CA002251714A patent/CA2251714A1/fr not_active Abandoned
- 1997-04-22 DE DE69726426T patent/DE69726426T3/de not_active Expired - Fee Related
- 1997-04-22 AU AU27418/97A patent/AU723447B2/en not_active Ceased
- 1997-04-22 US US09/155,956 patent/US6608030B1/en not_active Expired - Fee Related
- 1997-04-22 DK DK97921360T patent/DK0912601T4/da active
- 1997-04-22 ES ES97921360T patent/ES2208898T5/es not_active Expired - Lifetime
- 1997-04-22 EP EP97921360A patent/EP0912601B2/fr not_active Expired - Lifetime
- 1997-04-22 AT AT97921360T patent/ATE255126T1/de not_active IP Right Cessation
- 1997-04-22 WO PCT/US1997/006865 patent/WO1997040066A1/fr active IP Right Grant
- 1997-04-22 JP JP9538333A patent/JP2000509376A/ja active Pending
- 1997-04-22 PT PT97921360T patent/PT912601E/pt unknown
-
2002
- 2002-04-19 US US10/126,223 patent/US7285525B2/en not_active Expired - Fee Related
-
2003
- 2003-08-14 US US10/641,872 patent/US20050080010A1/en not_active Abandoned
-
2004
- 2004-08-05 US US10/913,045 patent/US7427591B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20030166534A1 (en) | 2003-09-04 |
EP0912601A1 (fr) | 1999-05-06 |
ATE255126T1 (de) | 2003-12-15 |
DE69726426T3 (de) | 2009-09-10 |
JP2000509376A (ja) | 2000-07-25 |
ES2208898T5 (es) | 2009-04-16 |
EP0912601B1 (fr) | 2003-11-26 |
AU723447B2 (en) | 2000-08-24 |
US20050095248A1 (en) | 2005-05-05 |
US7285525B2 (en) | 2007-10-23 |
US20050080010A1 (en) | 2005-04-14 |
US7427591B2 (en) | 2008-09-23 |
AU2741897A (en) | 1997-11-12 |
CA2251714A1 (fr) | 1997-10-30 |
ES2208898T3 (es) | 2004-06-16 |
PT912601E (pt) | 2004-04-30 |
DK0912601T3 (da) | 2004-03-29 |
NZ332390A (en) | 2000-07-28 |
US6608030B1 (en) | 2003-08-19 |
DE69726426D1 (de) | 2004-01-08 |
DE69726426T2 (de) | 2004-09-16 |
EP0912601B2 (fr) | 2008-11-05 |
WO1997040066A1 (fr) | 1997-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0912601T3 (da) | Suppression af immunrespons ved inhibering af cathepsin S | |
DK0643726T3 (da) | Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei | |
ATE415173T1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
NO983999L (no) | Peptidimmunogener for vaksinasjon mot og behandling av allergi | |
WO1998026747A3 (fr) | Procedes et compositions de traitement de maladies a base de superantigenes | |
YU46097A (sh) | Nova klasa estara i njihove farmaceutske smeše | |
CY1111079T1 (el) | Πεπτιδιο | |
ATE234111T1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
EP1071443A4 (fr) | Peptides isoles correspondant a des sequences d'acides amines de ny-eso-1 qui se lient a des molecules mhc de classe i et mhc de classe ii, et leurs utilisations | |
EP0716591A4 (fr) | PROCEDES ET COMPOSITIONS DESTINES A FIXER DES PROTEINES TAU ET MAP2c | |
GR3021421T3 (en) | Compositions for use in a method for treating a human suffering from multiple sclerosis | |
NO961423D0 (no) | Oligopeptider avledet fra C-reaktive proteinfragmenter | |
ATE310750T1 (de) | Verotoxin b untereinheit zur immunisierunug | |
ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
ATE239502T1 (de) | Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten |